|
BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. |
|
|
Research Funding - Lilly; Spectrum Pharmaceuticals; Takeda/Millennium |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Exact Sciences; Nektar |
Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Ribon Therapeutics; Sanofi |
Research Funding - AstraZeneca; Janssen Research & Development; Takeda |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda |
|
|
Consulting or Advisory Role - AstraZeneca; EMD Serono; Lilly |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Alimera Sciences; MedTek |
Honoraria - Pfizer; Roche/Genentech |
Consulting or Advisory Role - Pfizer; Roche/Genentech |
Research Funding - Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer |
Consulting or Advisory Role - MedImmune |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie/Stemcentrx (Inst); ISA Pharmaceuticals (Inst); Medimmune (Inst); Pfizer (Inst); Turnstone Bio (Inst) |
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; ISA Pharmaceuticals |
|
|
Consulting or Advisory Role - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Epizyme; Genentech/Roche; HERON; Imedex; Lilly; MedImmune; Novartis; Takeda |
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; MedImmune; Merck; Millennium; Polaris; Seagen; Seagen |
Patents, Royalties, Other Intellectual Property - UptoDate |
|
|
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda |
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations |